Sarah Boyce
CIK: 0001629383
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (23 total)
- Sep 18, 2026RNA
Atrium Therapeutics, Inc.
Tax Payment(F)Direct126.4K shares at avg. $8.95$1.1M - Jun 26, 2026CTNM
Contineum Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
19K shares- - Feb 27, 2026RNA
Atrium Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
20K shares- - Feb 27, 2026RNAM
Avidity Biosciences, Inc.
Disposition(D)Direct474.9K shares- - Jan 21, 2026RNA
Avidity Biosciences, Inc.
Sale(S)Direct8K shares at avg. $72.45$579K - Jan 21, 2026RNA
Avidity Biosciences, Inc.
Sale(S)Direct6.4K shares at avg. $72.45$463K - Jan 7, 2026RNA
Avidity Biosciences, Inc.
Sale(S)Direct8.6K shares at avg. $72.23$619K - Dec 18, 2025RNA
Avidity Biosciences, Inc.
Gift(G)Direct29.2K shares- - Dec 17, 2025RNA
Avidity Biosciences, Inc.
Tax Payment(F)Direct15.7K shares at avg. $71.87$1.1M - Dec 17, 2025RNA
Avidity Biosciences, Inc.
Award(A)Direct31K shares- - Sep 5, 2025RNA
Avidity Biosciences, Inc.
Exercise(M)Direct50K shares at avg. $1.24$62K - Sep 5, 2025RNA
Avidity Biosciences, Inc.
Sale(S)Direct50K shares at avg. $49.95$2.5M - Aug 28, 2025RNA
Avidity Biosciences, Inc.
Exercise(M)Direct25K shares at avg. $1.24$31K - Aug 28, 2025RNA
Avidity Biosciences, Inc.
Sale(S)Direct25K shares at avg. $49.39$1.2M - Jun 26, 2025CTNM
Contineum Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
14.8K shares- - Mar 20, 2025RNA
Avidity Biosciences, Inc.
Sale(S)Direct31.5K shares at avg. $31.06$980K - Jan 21, 2025RNA
Avidity Biosciences, Inc.
Sale(S)Direct5.7K shares at avg. $28.59$162K - Jan 21, 2025RNA
Avidity Biosciences, Inc.
Sale(S)Direct4.7K shares at avg. $28.59$135K - Jan 6, 2025RNA
Avidity Biosciences, Inc.
Award(A)Direct82.5K shares- - Dec 18, 2024RNA
Avidity Biosciences, Inc.
Sale(S)Direct31.9K shares at avg. $32.66$1.0M - Sep 23, 2024RNA
Avidity Biosciences, Inc.
Sale(S)Direct32.9K shares at avg. $44.00$1.4M - Sep 19, 2024RNA
Avidity Biosciences, Inc.
Award(A)Direct62.5K shares- - Sep 19, 2024RNA
Avidity Biosciences, Inc.
Award(A)Direct62.5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 18, 2026 |  RNA Atrium Therapeutics, Inc. | Tax Payment(F) | 126,418 | $8.95 | $1,131,441 | Direct |
| Jun 26, 2026 |  CTNM Contineum Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 19,000 | - | - | Direct |
| Feb 27, 2026 | RNA Atrium Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 20,000 | - | - | Direct |
| Feb 27, 2026 |  RNAM Avidity Biosciences, Inc. | Disposition(D) | 474,861 | - | $0 | Direct |
| Jan 21, 2026 | RNA Avidity Biosciences, Inc. | Sale(S) | 7,993 | $72.45 | $579,093 | Direct |
| Jan 21, 2026 | RNA Avidity Biosciences, Inc. | Sale(S) | 6,394 | $72.45 | $463,245 | Direct |
| Jan 7, 2026 | RNA Avidity Biosciences, Inc. | Sale(S) | 8,576 | $72.23 | $619,444 | Direct |
| Dec 18, 2025 | RNA Avidity Biosciences, Inc. | Gift(G) | 29,159 | - | - | Direct |
| Dec 17, 2025 | RNA Avidity Biosciences, Inc. | Tax Payment(F) | 15,742 | $71.87 | $1,131,378 | Direct |
| Dec 17, 2025 | RNA Avidity Biosciences, Inc. | Award(A) | 31,000 | - | - | Direct |
| Sep 5, 2025 | RNA Avidity Biosciences, Inc. | Exercise(M) | 50,000 | $1.24 | $62,000 | Direct |
| Sep 5, 2025 | RNA Avidity Biosciences, Inc. | Sale(S) | 50,000 | $49.95 | $2,497,435 | Direct |
| Aug 28, 2025 | RNA Avidity Biosciences, Inc. | Exercise(M) | 25,000 | $1.24 | $31,000 | Direct |
| Aug 28, 2025 | RNA Avidity Biosciences, Inc. | Sale(S) | 25,000 | $49.39 | $1,234,700 | Direct |
| Jun 26, 2025 | CTNM Contineum Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 14,750 | - | - | Direct |
| Mar 20, 2025 | RNA Avidity Biosciences, Inc. | Sale(S) | 31,540 | $31.06 | $979,563 | Direct |
| Jan 21, 2025 | RNA Avidity Biosciences, Inc. | Sale(S) | 5,659 | $28.59 | $161,817 | Direct |
| Jan 21, 2025 | RNA Avidity Biosciences, Inc. | Sale(S) | 4,738 | $28.59 | $135,475 | Direct |
| Jan 6, 2025 | RNA Avidity Biosciences, Inc. | Award(A) | 82,500 | - | $0 | Direct |
| Dec 18, 2024 | RNA Avidity Biosciences, Inc. | Sale(S) | 31,855 | $32.66 | $1,040,384 | Direct |
| Sep 23, 2024 | RNA Avidity Biosciences, Inc. | Sale(S) | 32,880 | $44.00 | $1,446,723 | Direct |
| Sep 19, 2024 | RNA Avidity Biosciences, Inc. | Award(A) | 62,500 | - | $0 | Direct |
| Sep 19, 2024 | RNA Avidity Biosciences, Inc. | Award(A) | 62,500 | - | $0 | Direct |
1-23 of 23 transactions
About Boyce Sarah
Boyce Sarah (SEC CIK 0001629383) files insider reports with the SEC as Director of Atrium Therapeutics, Inc. (RNA), Director of Contineum Therapeutics, Inc. (CTNM) and President and CEO of Avidity Biosciences, Inc. (RNAM).
Signal8 holds 16 ownership filings by Boyce Sarah (1 Form 3, 15 Form 4), filed between Sep 23, 2024 and Sep 22, 2026. Those filings report 23 transactions, from Sep 19, 2024 to Sep 18, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Boyce Sarah's filings is in SAN DIEGO, CA.
Recent filings by Boyce Sarah
- Sep 18, 2026: Tax withholding of RNA shares (Form 4, code F).
- Jun 26, 2026: Grant or award of CTNM derivative securities (Form 4, code A).
- Feb 27, 2026: Grant or award of RNA derivative securities (Form 4, code A).
- Feb 27, 2026: Disposition to issuer transaction of RNAM shares (Form 4, code D).
- Jan 21, 2026: Open-market sales of RNA shares (2 lines, Form 4, code S).
Other insiders filing for Atrium Therapeutics, Inc. (RNA)
- Younis Husam, Chief Scientific Officer
- Hughes Steven George, Chief Medical Officer
- Flanagan W. Michael, Director
- Kenney Stephanie
- Gallagher Kathleen P.
- Winslow Brendan R., Chief Financial Officer